Enclomiphene Citrate Side Effects: Incidence Rates Across Clinical Trials

The direct answer

Enclomiphene citrate has never received FDA approval; the branded candidate (Androxal, from Repros Therapeutics, NDA 22-569) received Complete Response Letters and was withdrawn from active development, which means there is no FDA label to anchor dosing or adverse-event claims. What exists instead is a small set of sponsor-run Phase II and Phase III trials, mechanistic reasoning based on clomiphene pharmacology, scattered case reports, and voluntary FAERS submissions. These sources consistently describe headache, nausea, and hot flush as the most frequent adverse events and describe serious events and vision-related events as rare, but the precise percentage figures that circulate on secondary websites attributing specific numbers to specific trials could not be verified against the original publications for this draft. Readers and clinicians should treat exact incidence percentages as directional rather than established until a qualified reviewer confirms them against the primary papers.

What enclomiphene citrate is, and how it differs from clomiphene

Clomiphene citrate is a racemic mixture of two isomers: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). The two isomers behave differently in the body. Enclomiphene clears relatively quickly, while zuclomiphene has a much longer half-life and accumulates with repeated dosing. This pharmacologic difference is well established in the clomiphene literature and is the mechanistic basis for developing enclomiphene alone: the hope was that isolating the trans isomer would preserve the testosterone-raising, spermatogenesis-sparing effect of clomiphene while reducing the estrogenic adverse effects attributed to accumulated zuclomiphene.

Mechanistically, enclomiphene works as an estrogen receptor antagonist at the hypothalamus, blunting negative feedback so that luteinizing hormone (LH) and follicle-stimulating hormone (FSH) rise, which in turn raises endogenous testosterone. Because it does not accumulate the way zuclomiphene does, plasma estradiol is expected to stay closer to baseline than with racemic clomiphene, which is the theoretical basis for a milder estrogenic side-effect profile. This is a plausible, mechanistically grounded expectation rather than a result confirmed by a large, verified head-to-head trial.

Regulatory status: why there is no FDA label to rely on

Repros Therapeutics submitted a New Drug Application for enclomiphene citrate (marketed name Androxal, NDA 22-569). The FDA's own application-tracking page for this NDA is publicly viewable and confirms the application's non-approved status. (FDA Drug Approvals database, NDA 22-569)

Because the drug was never approved, there is no FDA-reviewed label, no FDA-mandated post-marketing surveillance program, and no officially adjudicated adverse-event incidence table for enclomiphene specifically. Everything currently available comes from the sponsor's own trial reports, independent observational reports, and voluntary adverse-event databases. This matters for how much weight any single incidence number deserves: a number from an FDA label reflects regulatory review; a number from a sponsor's own trial report reflects that trial's design and sample size; a number from FAERS reflects unverified, voluntarily submitted reports with no denominator.

Compounded enclomiphene citrate remains available through 503A and 503B compounding pharmacies as an off-label prescription. Off-label compounded use is not the same as an FDA-approved indication, and compounded products are not subject to the same manufacturing and labeling review as an approved drug. This status should be checked periodically, since compounding rules and enforcement priorities can change.

What the trial evidence actually supports

Enclomiphene citrate has been studied in small Phase II and Phase III trials in men with secondary hypogonadism, generally comparing it against topical testosterone gel and placebo over three to six months. Across these trials, the adverse events reported most often are headache, nausea, and hot flush, generally described as mild to moderate and often transient. Serious adverse events and treatment discontinuations attributable to the drug are described as uncommon in these reports.

The specific percentage figures often quoted for these categories (for example, headache in a particular percentage of one dose arm versus another) trace back to individual trial publications that this article did not independently verify against the source journal record. Because a wrong-paper citation is worse than no citation, this draft does not reproduce those percentages as fact. A qualified medical reviewer with database access should confirm the exact figures against the original Phase II and Phase III publications before any specific percentage is presented to readers as established.

What can be said with more confidence is the direction of the findings across the available trials: enclomiphene trials describe estradiol changes that stay closer to the normal male range than what is typically reported with racemic clomiphene, and trial reports describe sperm concentration as better preserved with enclomiphene than with exogenous testosterone therapy, which is expected mechanistically since exogenous testosterone suppresses the same LH/FSH axis that enclomiphene stimulates. This spermatogenesis-preserving direction is consistent with the drug's mechanism and is the main reason clinicians consider it for men who want to raise testosterone while preserving fertility, but it is worth noting this comes from trial-level observation in small populations, not from a large confirmatory study.

Visual symptoms: a known SERM-class concern, not a confirmed enclomiphene-specific rate

Vision-related adverse effects, including blurred vision and other visual disturbances, are a well-documented concern with clomiphene, and case reports describe visual symptoms with SERMs generally. For enclomiphene specifically, trial reports describe visual disturbance as occurring in only a small number of participants, generally transient and without permanent vision loss reported. Because enclomiphene lacks the long-accumulating zuclomiphene isomer, there is a mechanistic argument that visual risk should be lower than with racemic clomiphene, but this has not been confirmed in a trial designed and powered to detect that difference.

Clinically, any visual symptom that develops during enclomiphene use warrants prompt discontinuation and evaluation rather than watchful waiting, consistent with the general SERM-class precaution used for clomiphene. Persistent visual changes, new visual field loss, or flashes of light lasting more than a day or two are reasons for urgent evaluation rather than a wait-and-see approach.

Cardiovascular and hematologic considerations

The FDA's stated concern in declining to approve Androxal centered on insufficient long-term cardiovascular safety data, which is a documented part of the regulatory record for this NDA. This is a meaningful signal in itself: the agency's judgment was not that a specific adverse event had been proven, but that the available trials were too small and too short to rule one out. Any therapy that raises endogenous testosterone carries a mechanistic expectation of some rise in hematocrit (red blood cell concentration), since testosterone stimulates erythropoiesis. Trial reports describe this rise as smaller with enclomiphene than with topical testosterone gel, which fits the pharmacology (enclomiphene raises testosterone through the body's own regulatory axis rather than by direct exogenous dosing), but the total exposure across the available controlled trials is measured in patient-months, not patient-years, which is too small a base to detect uncommon events like venous thromboembolism.

Enclomiphene versus clomiphene: what is established and what is not

It is mechanistically well established that racemic clomiphene contains the long-accumulating zuclomiphene isomer and that enclomiphene does not. It is a reasonable, evidence-consistent inference that this should translate into fewer estrogenic side effects (hot flush, mood change, visual symptoms) with enclomiphene than with clomiphene over comparable treatment durations. It is not established by a large, verified, head-to-head randomized trial that this actually happens at a specific, quantifiable rate. Smaller observational comparisons exist in the literature and generally support the direction of this expectation, but this article does not reproduce specific percentage comparisons from those studies because the underlying citation could not be verified here.

Post-market signals: what FAERS can and cannot tell you

Because enclomiphene has never been FDA-approved as a branded drug, it does not have the pharmacovigilance infrastructure that comes with approval. Reports involving compounded enclomiphene may be filed under "clomiphene," under "enclomiphene," or miscoded entirely, and FAERS reports are voluntary, unverified, and have no reliable denominator, so they cannot generate a true incidence rate. Readers can look up current reports directly on the FDA's public dashboard rather than relying on a specific count reproduced in an article, since report totals change over time. (FDA Adverse Event Reporting System (FAERS) Public Dashboard)

Monitoring and when to seek urgent care

Reasonable clinical practice for anyone using enclomiphene off-label generally includes baseline and follow-up testosterone, LH, FSH, and estradiol, along with periodic hematocrit checks, since these track the mechanism directly. General hypogonadism-treatment guidelines from bodies like the Endocrine Society address monitoring for testosterone-restoring therapies broadly; these guidelines were written primarily with exogenous testosterone therapy in mind and do not specifically address enclomiphene, so applying them to enclomiphene is a matter of clinical judgment rather than a guideline-endorsed protocol for this specific drug.

Seek urgent evaluation, rather than waiting for a routine follow-up, for: visual symptoms that persist beyond a day or two, chest pain or shortness of breath, calf swelling or pain suggestive of a blood clot, sudden or severe testicular pain (as opposed to mild pressure or fullness), or signs of an allergic reaction. These are general red-flag symptoms consistent with the mechanisms discussed above, not a claim that enclomiphene has been shown to cause any of them at a specific rate.

A framework for weighing any enclomiphene side-effect number you read

Because so much of the enclomiphene safety conversation online repeats numbers whose original source is hard to trace, use this checklist before treating any specific incidence figure as fact:

1. Is there an FDA label behind it? No. Enclomiphene has no FDA-approved label, so no percentage can be sourced to one. Any claim implying an "FDA-reported rate" for enclomiphene should be treated as incorrect.
2. Is it from a named, checkable trial? If a source cites a specific trial by author and year, ask whether that paper is retrievable and actually reports the number as stated. If the citation cannot be found or does not match, discard the number rather than repeat it.
3. Is it from FAERS? FAERS counts are real submissions but have no denominator and are not incidence rates. A FAERS count tells you a symptom has been reported, not how often it happens.
4. Is it from a guideline? Guidelines on testosterone therapy monitoring were generally written for exogenous testosterone, not for enclomiphene specifically. Useful for what to monitor; not proof of an enclomiphene-specific rate.
5. What follows from this, practically? Even without a confirmed number, the consistent pattern across sources is: headache, nausea, and hot flush are the most commonly reported symptoms and are usually mild and self-limited; visual symptoms and serious events are reported infrequently but the evidence base is too small to rule out rare risks. Use that pattern to set expectations and monitoring frequency with a prescriber, not a specific percentage to memorize.

What is established, what is plausible, and what is not established

Established: Enclomiphene citrate is the trans-isomer of clomiphene, mechanistically distinct from the long-accumulating zuclomiphene isomer. It has no FDA-approved indication as of 2025; the Androxal NDA did not reach approval. It is available only through off-label compounded prescribing.

Plausible but not confirmed by a large verified trial: That enclomiphene causes meaningfully fewer estrogenic side effects than racemic clomiphene at a specific, quantifiable rate. That its cardiovascular and hematologic risk profile over long-term use (beyond the several months studied in available trials) matches its short-term profile.

Not established: Any single precise incidence percentage for a named adverse event in a named enclomiphene trial, as reproduced across secondary sources, since this article could not verify those figures against the original publications. Long-term (multi-year) safety data, since no controlled trial of that duration is publicly available.